LCTX - Lineage Cell Therapeutics, Inc.

QQQ $ 609.13 $ 9.59 (1.6 %)

DIA $ 471.96 $ 0.54 (0.11 %)

SPY $ 672.20 $ 6.74 (1.01 %)

TLT $ 88.91 $ -0.87 (-0.97 %)

GLD $ 376.11 $ 3.22 (0.86 %)

Previous Close

$ 1.8

Open

$ 1.87

Bid

$ 1.86 x 1,312

Ask

$ 1.87 x 1,482

Day's Range

$ 1.81 - $ 1.95

52 Week Range

$ 0.37 - $ 2.09

Volume

1,624,502

Average Volume

Market Cap

414.59M

Beta (5Y Monthly)

$ 1.17

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-06-2025	09-30-2025	10-Q
2	08-12-2025	06-30-2025	10-Q
3	05-13-2025	03-31-2025	10-Q
4	03-10-2025	12-31-2024	10-K
5	11-14-2024	09-30-2024	10-Q
6	08-08-2024	06-30-2024	10-Q
7	05-09-2024	03-31-2024	10-Q
8	03-07-2024	12-31-2023	10-K
9	11-09-2023	09-30-2023	10-Q
10	08-10-2023	06-30-2023	10-Q
11	05-11-2023	03-31-2023	10-Q
12	03-09-2023	12-31-2022	10-K
13	11-10-2022	09-30-2022	10-Q
14	08-11-2022	06-30-2022	10-Q
15	05-12-2022	03-31-2022	10-Q
16	03-10-2022	12-31-2021	10-K
17	11-10-2021	09-30-2021	10-Q
18	08-12-2021	06-30-2021	10-Q
19	05-13-2021	03-31-2021	10-Q
20	03-11-2021	12-31-2020	10-K
21	11-04-2020	09-30-2020	10-Q
22	08-06-2020	06-30-2020	10-Q
23	05-07-2020	03-31-2020	10-Q
24	03-12-2020	12-31-2019	10-K
25	11-12-2019	09-30-2019	10-Q
26	08-08-2019	06-30-2019	10-Q
27	05-09-2019	03-31-2019	10-Q
28	03-14-2019	12-31-2018	10-K
29	11-08-2018	09-30-2018	10-Q
30	08-02-2018	06-30-2018	10-Q
31	05-10-2018	03-31-2018	10-Q
32	03-15-2018	12-31-2017	10-K
33	11-09-2017	09-30-2017	10-Q
34	08-09-2017	06-30-2017	10-Q
35	05-10-2017	03-31-2017	10-Q
36	03-16-2017	12-31-2016	10-K
37	11-04-2016	09-30-2016	10-Q
38	08-09-2016	06-30-2016	10-Q
39	05-10-2016	03-31-2016	10-Q
40	03-15-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Lineage Cell Therapeutics Sold 12M Common ...
11/12/2025 14:29:45

On November 12, 2025, Lineage Cell Therapeutics, Inc. (the "Company") sold 12,000,000 common shares to Janus Henderson ...

Lineage Cell Therapeutics Q3 EPS $(0.13) M...
11/06/2025 21:01:48

Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimat...

Earnings Scheduled For November 6, 2025
11/06/2025 11:12:19

12 Health Care Stocks Moving In Monday's A...
09/22/2025 21:06:10

Lineage Cell Therapeutics Announces Launch...
09/08/2025 12:01:43

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogen...

5 Analysts Assess Lineage Cell Therapeutic...
08/27/2025 18:01:25

D. Boral Capital Maintains Buy on Lineage ...
08/27/2025 12:17:51

D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price tar...

Lineage And William Demant Collaborate Thr...
08/26/2025 12:05:34

Three-year term intended to advance preclinical development of ReSonanceUp to $12 million of development costs to be contribute...

12 Health Care Stocks Moving In Friday's I...
08/15/2025 17:07:19

D. Boral Capital Maintains Buy on Lineage ...
08/14/2025 12:32:34

D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price tar...

Update: Lineage Cell Therapeutics Q2 Adj. ...
08/12/2025 20:04:10

Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimat...

Lineage Cell Therapeutics Q2 EPS $(0.13) M...
08/12/2025 20:02:41

Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimat...

Earnings Scheduled For August 12, 2025
08/12/2025 08:32:28

A Peek at Lineage Cell Therapeutics's Futu...
08/11/2025 20:02:34

D. Boral Capital Maintains Buy on Lineage ...
08/05/2025 11:50:25

D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price tar...

Lineage Cell Therapeutics Announced The Fi...
08/04/2025 12:10:10

The DOSED study is designed to evaluate the safety and utility of a new parenchymal spinal delivery system, a novel delivery de...

D. Boral Capital Maintains Buy on Lineage ...
06/23/2025 13:26:16

D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price tar...

two-biotech-stocks-poised-for-big-moves-on-monday

Two Biotech Stocks Poised For Big Moves On...
06/23/2025 11:39:03

HC Wainwright & Co. Reiterates Buy on Line...
06/23/2025 11:21:13

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $...

Lineage's OpRegen Shows +9 Letter BCVA Gai...
06/23/2025 11:09:39

Mean vision gains of +9 letters among patients with extensive coverage of OpRegen cell therapy to the Geographic Atrophy (GA) l...